Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

This early-phase clinical trial is testing a new drug called NMS-03597812 in adults with relapsed or refractory acute myeloid leukemia (AML) — a fast-growing blood cancer that has come back or stopped responding to treatment. The study starts with finding the right safe dose (Phase Ia) and then tests it in specific patient groups, including those with a TP53 mutation. **You may be eligible if...** - You are an adult with AML that has come back or is not responding to standard treatment - You have already tried standard therapies such as intensive chemotherapy, hypomethylating agents with venetoclax, FLT3 inhibitors, or IDH inhibitors — and they did not work - Your organ function (heart, liver, kidneys) meets the required levels - You are in reasonable physical condition **You may NOT be eligible if...** - You have not yet tried available standard treatments - You have active brain involvement from leukemia - You have active uncontrolled infections - You have recently received other experimental drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.